Matt Lyons’ Venture, Extremity Medical, Next Gen Bone Cell Graft
Biloine W. Young • Tue, October 24th, 2017
Extremity Medical, LLC, of Parsippany, New Jersey, announces the release of its next generation viable bone cell graft for use in surgery on the foot, ankle, wrist and hand—BioFuse. According to the firm’s press release, this live cell graft supplies the physiologic and essential components needed for robust bone formation. Among them are osteogenic cells, osteoinductive (biologic stimulants), and an osteoconductive (scaffold).
Company officials state that the company utilizes proprietary processing advancements focused on providing faster harvesting, and a significant reduction in the exposure to harmful stressors that can damage cells during processing.
The company maintains that, in vitro testing indicates that BioFuse provides higher levels of osteoinductive biologic stimulants, and increased osteoconductivity as compared to traditionally processed live bone cell grafts.
Matt Lyons, Chairman and CEO of Extremity Medical commented, “BioFuse is a next generation viable bone matrix that will have a significant impact on the bone graft market for the extremities. This addition to the growing Extremity Medical portfolio will complement our current and planned product portfolio for 2017 and beyond and aligns with our continued goal to release innovative products that will significantly impact the extremity surgeon’s ability to treat challenging patient conditions.”